Kidney-accumulating olmesartan-loaded nanomicelles ameliorate the organ damage in a murine model of Alport syndrome

CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome

(2020) Sang Heon Suh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome

(2020) Oliver Gross et al.   KIDNEY INTERNATIONAL

Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease

(2020) Dandan He et al.   HORMONE AND METABOLIC RESEARCH

Mind your assays: Misleading cytotoxicity with the WST-1 assay in the presence of manganese

(2020) Eleonora Scarcello et al.   PLoS One

Glycol chitosan-based renal docking biopolymeric nanomicelles for site-specific delivery of the immunosuppressant

(2020) Chang Seong Kim et al.   CARBOHYDRATE POLYMERS

Arterial Stiffness Predicts General Anesthesia–Induced Vasopressor-Resistant Hypotension in Patients Taking Angiotensin-Converting Enzyme Inhibitors

(2020) Kenichi Ueda et al.   JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA

Gut microbiota regulates lacteal integrity by inducing VEGF‐C in intestinal villus macrophages

(2019) Sang Heon Suh et al.   EMBO REPORTS

A polymeric micelle with an endosomal pH-sensitivity for intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin

(2019) Xiaohui Pu et al.   Acta Biomaterialia

Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ

(2019) Suh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial

(2018) Marie Mide Michelsen et al.   PLoS One

Manipulation of pH-Sensitive interactions between podophyllotoxin-chitosan for enhanced controlled drug release

(2017) Chao Chen et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome

(2017) Eun Hui Bae et al.   KIDNEY INTERNATIONAL

Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis

(2016) G. E. Callera et al.   BIOSCIENCE REPORTS

Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis

(2016) Junhui Gu et al.   KIDNEY & BLOOD PRESSURE RESEARCH

How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT—a prospective cohort study

(2015) Paola Cianfrone et al.   JOURNAL OF NEPHROLOGY

Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats

(2015) Yi-Ming Yuan et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors

(2014) Raphael N. Vuille-dit-Bille et al.   AMINO ACIDS

Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats

(2013) Vengadeshprabhu Karuppa Gounder et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane Nephropathy

(2013) J. Savige et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1–7 mas receptor

(2012) Vijayakumar Sukumaran et al.   FREE RADICAL RESEARCH

Alport syndrome—insights from basic and clinical research

(2012) Jenny Kruegel et al.   Nature Reviews Nephrology

Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome

(2012) Nicholas J. A. Webb et al.   PEDIATRIC NEPHROLOGY

Olmesartan Induces Renoprotective Effects by Stimulating Angiotensin Type 2 Receptors and Reducing Oxidative Stress in Diabetic Nephropathy

(2011) Fusakazu Jo et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis

(2011) Luigi Villa et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Olmesartan Ameliorates Progressive Glomerular Injury in Subtotal Nephrectomized Rats through Suppression of Superoxide Production

(2008) Sohachi FUJIMOTO et al.   HYPERTENSION RESEARCH

Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells

(2008) TORU KAGAWA et al.   NEPHROLOGY